Kennedy to oust care task force, WSJ reports; HHS says no decision yet
WASHINGTON (Reuters) -U.S. Health Secretary Robert F. Kennedy Jr. is planning to remove all the members of an advisory panel that determines what cancer screenings and other preventive health measures insurers must cover, the Wall Street Journal reported on Friday, citing people familiar with the matter.
A Department of Health and Human Services spokesperson said on Friday that Kennedy had not yet made a decision regarding the 16-member U.S. Preventive Services Task Force.
"No final decision has been made on how the USPSTF can better support HHS' mandate to Make America Healthy Again," the HHS spokesperson said.
The Journal said Kennedy planned to dismiss all 16 panel members in what would be the latest in a series of far-reaching actions by Kennedy, a long-time vaccine skeptic, to reshape U.S. regulation of vaccines, food and medicine.
In June he fired all 17 members of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, a panel of vaccine experts, replacing them with seven handpicked members, including known vaccine skeptics.
The USPSTF includes medical experts serving staggered four-year terms on a volunteer basis. Its role in choosing what services will be covered by insurers was established under the 2010 Affordable Care Act, also known as Obamacare.
The 40-year-old group, whose recommendations provide guidance to doctors, looks at everything from routine breast cancer screening to drugs to prevent HIV infection.
The U.S. Supreme Court in June upheld the constitution of the task force and ruled in favor of its recommendation to cover preventive care.
Though made up of an independent group of volunteer experts, members are selected by the health secretary without Senate confirmation and it relies on support from the department's Agency for Healthcare Research and Quality.
A group of 104 health organizations, including the American Medical Association and the American Academy of Pediatrics, in early July sent a letter to Congressional health committees, urging them "to protect the integrity" of the task force.
The task force has been criticized by some conservatives as too left-leaning.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial
We recently compiled a list of CG Oncology, Inc. stands sixth on our list. CG Oncology, Inc. (NASDAQ:CGON) is a late-stage clinical biopharmaceutical company developing bladder-sparing immunotherapies, with a primary focus on cretostimogene grenadenorepvec, a targeted oncolytic virus therapy for bladder cancer. Their lead program targets high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), an area with limited options beyond invasive surgery. Recent data from the Phase 3 BOND-003 trial, presented in June 2025, revealed a 75.5% complete response rate, with 42.3% of patients maintaining that response at 24 months. Impressively, 97.3% remained free of progression to muscle-invasive disease, and 91.6% avoided cystectomy. The therapy was also well-tolerated, with no grade 3 or higher treatment-related adverse events reported. Cretostimogene stands out as a potential new standard for NMIBC, offering durable cancer control without surgery and preserving patients' quality of life. Its promising results have sparked interest in combining it with other therapies like pembrolizumab, further expanding its therapeutic potential. A healthcare specialist in the laboratory testing an Oncology-related product. CG Oncology, Inc. (NASDAQ:CGON) continues to expand its clinical footprint with trials targeting both BCG-naïve and previously treated patients. A Biologics License Application (BLA) is expected soon, supported by strong Phase 2 combination data published in Nature Medicine. The business is also offering expanded access programs, broadening patient reach before full regulatory approval. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
17 minutes ago
- Yahoo
Kids are always watching. What are you teaching them about burnout?
"You don't have to earn a break." As a parent, you're constantly multitasking — anticipating your children's needs, managing their emotions and keeping everything running smoothly. It's no wonder you're tired. Some days (or most days) you may feel like you need to keep pushing yourself, even when you've already hit your limit. This can lead to burnout, a persistent exhaustion that even a good night's rest can't remedy. Actually taking a break and cutting yourself some slack may feel like a foreign concept or a luxury, but here's something to remember: Your kids are watching how you take care of yourself (or don't) and are learning from you. In the 10th episode of their podcast, After Bedtime With Big Little Feelings, Big Little Feelings founders Kristin Gallant, a parenting coach with a background in maternal and child education, and Deena Margolin, a child therapist specializing in interpersonal neurobiology, break down the science of burnout, how to stop the stress cycle and why the usual suggestions (take a hot bath! Have a glass of wine!) don't necessarily work. In this edition of Yahoo's "" column, Gallant talks about how, consciously or not, we often learn to keep pushing ourselves by watching our parents do the same — and how we can unintentionally pass those unhealthy habits on to our kids. Gallant also shares four phrases parents can use to model honoring your limits and showing that you don't have to prove your worth as a parent by burning yourself out. If you're exhausted and wondering why — why you can't rest, why you feel guilty when you do, why it feels like no matter how much you give, it's never enough — you're not alone. You're likely not just burned out. You're part of a generational cycle of burnout that's been quietly passed down for decades. Here's how to spot it, stop it and raise the first generation that doesn't have to earn their worth through overdoing it. What messages did we absorb growing up? Many of us grew up watching moms who never sat down, dads who never stood still or caregivers who gave and gave until there was nothing left in the tank. We absorbed messages like: 'Busy = valuable.' 'Rest = laziness.' 'Self-sacrifice = love.' Even if no one said it out loud, the message was clear: Your worth is measured by how much you do — not how you feel. It's not about blaming our parents. It's about seeing the invisible rules we were given so we don't hand them to our kids. If burnout was treated like a badge of honor in your childhood — 'My mom did it all and never complained!' — you probably learned that running on empty is just the price of being a good mom, a good partner, a good person. And when burnout is invisible, we're less likely to recognize it in ourselves … until it's too late. How burnout sneaks into our parenting scripts You might not even notice it. But burnout is hiding in the tiny things we say: 'Be strong.' 'Push through.' 'We don't quit.' 'Come on, you're fine.' They sound innocent enough. But they reinforce the idea that emotions are inconvenient, limits are shameful, and your body is something to override, not listen to. The pressure to be a 'good mom' is literally burning us out Modern motherhood has become a trap: Be a 1950s housewife. With a 2020s career. With zero help. And no margin for error. If you're not constantly self-improving, baking from scratch and being emotionally attuned 24/7 while balancing a full-time job, you feel like you're failing. The truth? The 'superwoman' myth isn't empowering. It's exploitative. It keeps us isolated, overwhelmed and convinced we're the problem, when really, the system is. How to raise kids who don't tie their worth to pushing themselves until burnout We model something different. Even if it feels radical. Even if it's deeply uncomfortable at first. We say: 'I'm tired, so I'm resting.' 'You don't have to earn a break.' 'Your feelings matter.' 'Your limits are allowed.' We show our kids that asking for help isn't a weakness, it's wisdom. That worth isn't earned through doing, it's inherent. We break the cycle not through perfection, but through presence — through brave, tiny moments of choosing ourselves, so our kids learn they can choose themselves too. Want to raise a child who doesn't burn out at 35? Let them see you rest. Let them see you say no. Let them see you choose your own humanity. That's how the cycle ends. That's how the healing begins. Solve the daily Crossword
Yahoo
17 minutes ago
- Yahoo
Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy
We recently compiled a list of Denali Therapeutics Inc. stands sixth on our list among the best future stocks. Denali Therapeutics Inc. (NASDAQ:DNLI) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, focused on developing therapies for neurodegenerative and lysosomal storage disorders. Its proprietary TransportVehicle (TV) technology enables the delivery of biologics across the blood-brain barrier, targeting neurological symptoms often left untreated by conventional therapies. In July 2025, the company achieved a major milestone as the FDA accepted and granted Priority Review for its Biologics License Application (BLA) for tividenofusp alfa, a novel enzyme replacement therapy for Hunter syndrome (MPS II). This designation highlights the urgent medical need and sets a PDUFA decision date of January 5, 2026, opening the door for potential approval and launch by early 2026. Tividenofusp alfa is a first-in-class brain-penetrant enzyme therapy designed to overcome a key limitation of current treatments, which do not reach the brain and fail to address neurological symptoms. In clinical trials, Denali Therapeutics Inc. (NASDAQ:DNLI)'s therapy demonstrated effective delivery of the missing enzyme to the central nervous system, showing promise for addressing both somatic and neurological aspects of Hunter syndrome. A scientist in a labcoat inspecting a microscope focusing on a microorganism related to the biopharmaceutical company's therapies. If approved, this therapy would not only offer new hope for patients with Hunter syndrome but also validate the corporation's TV platform, accelerating the development of additional treatments for other disorders like Sanfilippo syndrome (DNL126) and other central nervous system diseases. The milestone marks a transformative moment for Denali Therapeutics Inc. (NASDAQ:DNLI), potentially expanding its leadership in next-generation rare disease therapies. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
